News Article | April 17, 2017
In their March Ophthalmology Business article titled “The Shifting Role of the Modern Ophthalmic Administrator,” Medical Consulting Group Founder and Managing Principal William B. Rabourn and Hollingshead Eye Center Chief of Financial and Operations Louis Pennow reveal one of the best ways for administrators to adapt to their ever-mounting responsibilities and ensure practice profitability. Rabourn says the main issue is that many doctors are currently caught up in their own changing roles within the practice. They have yet to realize how the administrator’s “bucket” of job responsibilities has grown so full that it is unrealistic to expect one person to effectively tackle every crucial item on the practice management list. “Our aim with this article was to reveal how outsourcing, if done well and managed by a qualified administrator, could revitalize a practice,” says Pennow. RABOURN Bill Rabourn has 28 years of comprehensive experience in business strategy with a specialty in medical business. He provides consulting and creative services to a select group of medical and surgical ophthalmology and plastic surgery practices. Visit MedCGroup.com to contact him or to learn more. PENNOW Louis Pennow has more than 25 years of experience in managing high-volume refractive and cataract practices. Visit HollingsheadEyeCenter.com to contact him or to learn more.
News Article | May 15, 2017
The A-Scan Plus Connect®, in use at all five Perich Eye Center clinics, is the single most effective solution for measuring cataracts, calculating sizes and densities, and refining surgical outcomes. -- Perich Eye Center has added the industry's leading cataract measurement technology at its five offices, promising an improved patient experience for those facing refractive cataract surgery.The A-Scan Plus Connect, in use at every Perich Eye Center location, is the single most effective solution for measuring cataracts, calculating sizes and densities, and refining surgical outcomes. The state-of-the-art technology is effective with dense cataracts, and on patients with fixation difficulties.The A-Scan Plus Connect, made by Accutome, measures cataracts with ultimate precision and, because of its rapid measurement capture, means less time in the chair for patients. Measurement data is quickly and completely available to the entire refractive cataract surgery team via an improved user interface, complete portability for connecting with tablets or laptops, and streamlined data sharing."We're thrilled to adopt this top-line cataract measurement technology for its tremendous medical benefits, and also to improve the entire patient experience at our offices," said Dr. Larry M. Perich ( http://www.pericheye.com/ 73/Dr.-Larry- M.-Perich ) of Perich Eye Center ( http://www.pericheye.com/ ). "The A-Scan Plus Connectallows us to measure cataracts with amazing accuracy, and minimize time and discomfort in the process. Our patients benefit at every step."Improving patient care through technology is a continual process at Perich Eye Center. The central Florida eye care provider recently added several Outcome Health technology platforms at its offices to share information with patients for better education and engagement.With five locations, Perich Eye Centers serve the ever-changing eye care needs of greater Tampa and central Florida through state-of-the-art ophthalmological treatment, and ensuring measured outcomes that meet or exceed patient expectations. Its professional medical staff's expertise is backed by decades of research, education and training. Patient needs are always the guiding force in the clinic's ongoing pursuit of excellence, using the highest standards of quality and ethical values.More information is available by calling (727) 372-1311 or visiting www.pericheye.com.
News Article | June 1, 2017
"The day we transplanted a PDEK graft successfully at the Duke Eye Center was the epitome of my time here at Duke," Dr. Nariani says. "It was the day when we embarked on the transition from older forms of corneal transplantation to one that has the potential to utilize young donor cells while maintaining thin grafts, thereby enhancing optical clarity." "I believe that Miracles In Sight, by offering this exquisitely prepared donor PDEK tissue, is bringing in an era of a new and elevated standard for eye banking in the U.S.," Dr. Carlson says. The PDEK procedure involves injecting an air bubble into a donated cornea. The air bubble isolates the cornea's endothelium, Descemet's membrane, and the newly described Dua's Layer, creating a graft that is roughly 35 micrometers in thickness. "Two procedures – DSAEK and DMEK – are currently the most widely performed types of endothelial keratoplasty procedures," explains Isaac Perry, Director of Clinical Services at Miracles In Sight. "The current feedback from surgeons is that PDEK combines some of the advantages of each type of procedure, and may offer better outcomes for their patients." Perry adds, "We've worked tirelessly on perfecting this preparation technique for a year and a half. To see such a positive outcome and success is truly rewarding." Each year, MIS sponsors a cornea fellow at Duke. Dr. Nariani was last year's fellow, and culminated her fellowship with the PDEK transplant. "I am proud of the work done by Duke Eye Center and the Miracles In Sight Eye Bank," Dr. Nariani says. "Special thanks to Dr. Agarwal for helping us make the transition here in the United States." Currently, MIS provides corneas for more than 3,600 transplants each year. MIS has been providing eye banking services since 1951. In its more than 65-year history, the organization has developed well-known processes that ensure quality corneal tissue is delivered in a timely way to surgeons. As part of its mission, MIS provides extensive training and support opportunities for physicians and their staff, including scholarships for qualified surgeons to attend advanced industry training seminars, onsite training of physicians' office staff, and financial support for academic training at University hospitals in North and South Carolina. Miracles In Sight also hopes the successful surgery serves as a call to action for more people to become organ, eye and tissue donors. Our mission is to support the restoration, preservation and enhancement of sight through transplant, research, education and innovation. For more information about Miracles In Sight, the donation process and how you can become a donor, please visit www.miraclesinsight.org Miracles In Sight (formerly the North Carolina Eye Bank), based in Winston-Salem, NC, USA is one of the largest eye banks in the world. The mission of Miracles In Sight is to recover, process and distribute ocular tissue for the restoration of sight through corneal transplantation and related medical therapy and research. A significant part of this mission is stewardship focused on training and educating the medical community and supporting partners and organizations around the world. To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/winston-salem-nc-based-miracles-in-sight-plays-critical-role-in-brand-new-surgical-technique-set-to-transform-corneal-transplantation-300467140.html
News Article | May 30, 2017
Un outil diagnostique révolutionnaire améliore de manière significative les résultats pour les patients astigmates qui subissent une chirurgie réfractive de la cataracte TORONTO, ONTARIO--(Marketwired - 30 mai 2017) - Alcon Canada, une division d'Alcon (le chef de file mondial en matière de soins oculaires), a fait l'annonce suivante aujourd'hui : le Valley Laser Eye Centre d'Abbotsford (C.-B.) est récemment devenu le premier établissement au Canada à offrir le système ORAMC doté de la technologie VerifEyeMC à ses patients ayant besoin d'une chirurgie de la cataracte. Le système ORAMC doté de la technologie VerifEyeMC est un aberromètre peropératoire qui permet le guidage par images et qui transmet en temps réel des données fiables aux ophtalmologistes. Ces derniers peuvent ainsi choisir la position et la puissance de la lentille intraoculaire de technologie avancée appropriées durant la chirurgie de la cataracte. « Le système ORAMC doté de la technologie VerifEyeMC est un outil très précieux pour les chirurgiens. Il permet d'améliorer les résultats liés à la vision après l'intervention, et ce, même chez les patients ayant déjà subi une correction de la vision au laser ou une photokératectomie réfractive », a dit le Dr John Blaylock, FRCSC, du Valley Laser Eye Center. « L'aberrométrie peropératoire ORA est le plus important progrès technologique dans le domaine de la chirurgie de la cataracte et de l'échange de lentille réfractive depuis l'arrivée de la chirurgie de la cataracte assistée par laser », a dit le Dr Blaylock. Plus tôt ce mois-ci, ce dernier a mené une discussion sur l'aberrométrie peropératoire lors de la réunion annuelle de la B.C. Society of Eye Physicians and Surgeons. D'après une étude, l'utilisation du système ORAMC doté de la technologie VerifEyeMC a permis de réduire de près de 54 % le nombre de patients qui n'atteignaient pas l'objectif prévu d'astigmatisme1. Le système s'est aussi révélé efficace dans les cas plus complexes, comme chez les patients ayant déjà subi une correction de la vision au laser. D'après une étude connexe, 45 % plus de patients ayant déjà subi ce type d'intervention atteignaient l'objectif de réfraction prévu pour la chirurgie de la cataracte lorsque celle-ci était réalisée avec le système ORA (comparativement aux chirurgies réalisées sans le système)2. « Le système ORAMC doté de la technologie VerifEyeMC joue le rôle d'une "police d'assurance" », dit Brian Chan, chef de produits principal, CORE, Lasers pour chirurgie réfractive et de la cataracte chez Alcon Canada. « Il permet aux chirurgiens de vérifier leurs mesures et de détecter les problèmes liés à la réfraction tout au long de l'intervention, y compris durant les moments cruciaux suivant le retrait du cristallin du patient qui présente une cataracte. » Utiliser ou non le système ORAMC doté de la technologie VerifEyeMC peut avoir d'autres répercussions importantes sur la qualité de vie des patients. « Le patient pourrait devoir porter des lunettes ou non après la chirurgie de la cataracte », dit M. Chan. En plus d'offrir une grande exactitude, le robuste logiciel du système (compatible avec toute la suite cataracte-réfraction d'Alcon) peut analyser les résultats après la chirurgie réfractive, et permettre aux chirurgiens de les comparer avec ceux de leurs collègues partout dans le monde. Selon le Dr Blaylock, « la précision du système ORA élimine l'incertitude liée à la prévision des résultats de la chirurgie réfractive, et réduit grandement le besoin de retirer et de remplacer les lentilles, ce qui est avantageux pour ma pratique et surtout pour mes patients. » Pour en savoir plus sur le système ORA, visitez le site : http://bit.ly/AlconOra Les cataractes sont la première cause de cécité traitable dans le monde. Elles touchent plus de 240 millions de personnes à l'échelle du globe, et sont fréquentes chez les gens de 55 ans et plus. En tant que chef de file mondial en matière de dispositifs médicaux et d'instruments associés à la chirurgie de la cataracte, Alcon offre la gamme de produits chirurgicaux la plus complète de l'industrie pour la chirurgie de la cataracte (notamment des instruments pour ce type d'intervention). Elle offre aussi des lentilles intraoculaires pour le traitement des cataractes et pour la correction de troubles liés à la réfraction, comme la presbytie et l'astigmatisme. Alcon Canada, une division d'Alcon, chef de file mondial en matière de soins oculaires, offre des produits novateurs qui améliorent la qualité de vie des gens du monde entier en leur procurant une meilleure vision. Les deux divisions d'Alcon - Applications chirurgicales et Soins oculaires - offrent le plus vaste éventail de produits de soins oculaires au monde. Alcon est la deuxième division en importance du Groupe Novartis, son chiffre d'affaires net ayant atteint 5,8 milliards de dollars américains en 2016. Alcon, dont le siège social est situé à Fort Worth, au Texas, est présente dans 75 pays, et ses produits sont en vente sur 180 marchés. Pour obtenir de plus amples renseignements, visitez le site : www.alcon.ca/fr
News Article | May 30, 2017
TORONTO, ONTARIO--(Marketwired - May 30, 2017) - Alcon Canada, a division of Alcon, the global leader in eye care, announced today that the Valley Laser Eye Centre, in Abbotsford, BC, recently became the first facility in Canada to offer the ORA System™ with VerifEye™ technology to patients requiring cataract surgery. The ORA System™ with VerifEye™ technology is an intraoperative aberrometer that provides real-time, reliable data and image guidance to ophthalmologists, so they can more accurately select the appropriate advanced intraocular lens (ATIOL) power and placement during cataract surgery. The ORA System™ with VerifEye™ technology is a powerful tool for surgeons in helping to improve post-operative visual outcomes, even with patients who have previously undergone laser vision correction or photorefractive keratectomy surgery, said Dr. John Blaylock, MD FRCSC, of the Valley Laser Eye Center. "ORA intraoperative aberrometry is the most significant technical advancement in cataract surgery and refractive lensectomy since laser-assisted cataract surgery," said Blaylock, who led a discussion earlier this month on Intraoperative Aberrometry at the B.C. Society of Eye Physicians and Surgeons' Annual meeting. According to one study, the ORA System™ with VerifEye™ technology lowered the number of patients who fell outside of their intended astigmatic target by almost 54%.1 The system has also proven effective in more challenging cases, such as patients who have previously undergone laser vision correction, with a related study finding that among those patients who had previously undergone laser vision correction surgery, 45% more were able to reach their intended refractive target when surgeons performed cataract surgery with the aid of the ORA system than without it.2 "The ORA System™ with VerifEye™ Technology acts as an 'insurance policy'," says Brian Chan, Sr. Product Manager, CORE Cataract and Refractive Lasers at Alcon Canada, "It allows surgeons to verify their measurements and identify any refractive issues throughout a surgery, including during those crucial moments after they've removed the natural lens of a patient that's been impacted by cataracts." Whether or not a surgeon uses the ORA System™ with VerifEye™ technology can pose other significant quality of life implications for patients. "It can mean the difference between needing to wear glasses after cataract surgery or not," Chan said. In addition to its accuracy, the system's robust software, which supports Alcon's entire cataract refractive suite, can perform post-op analysis on refractive outcomes and enable surgeons to compare their results with those of their colleagues around the globe. Says Blaylock, "The precision of the ORA not only takes the guesswork out of predicting refractive outcomes, but it significantly reduces the need to explant and replace lenses, which benefits my practice and, most importantly, my patients." For more information on the ORA, visit: http://bit.ly/AlconOra Cataracts are the leading cause of treatable blindness worldwide. They affect over 240 million people globally and are widespread among people 55 and older. As the global leader in cataract surgical equipment and medical devices, Alcon offers the industry's most complete line of surgical products for cataract surgery, including equipment for cataract procedures, as well as IOLs to treat cataracts and correct refractive conditions, like presbyopia and astigmatism. Alcon Canada, a division of Alcon, the global leader in eye care, provides innovative products that enhance quality of life by helping people worldwide see better. Alcon's two businesses, Surgical and Vision Care, offer the widest spectrum of eye care products in the world. Alcon is the second-largest division of the Novartis Group, with net sales of USD 5.8 billion in 2016. Headquartered in Fort Worth, Texas, USA, Alcon has operations in 75 countries and products available in 180 markets. For more information, please visit: www.alcon.ca
News Article | May 25, 2017
Current patients can continue to expect the same services and level of care they received for more than 30 years, and now can receive the additional expertise of renowned ophthalmologists, Dr. Jitendra Swarup and Dr. Peter Mitrev. Dr. Swarup is eastern North Carolina's leading laser cataract surgeon, and Dr. Mitrev is a board-certified, fellowship trained glaucoma specialist. Also, the Outer Banks location is adding a new Optometrist, Nicholas E. Bem, OD. "This is going to be a natural progression for both practices," says Dr. William Blakemore, owner of Edenton and Outer Banks Eye Care, of the merger. "We're going to maintain the same expertise in Edenton and the Outer Banks that we have provided for years, with the addition of some other specialty services for these communities." Albemarle Eye Center provides expert LenSx surgery for the treatment of cataracts, lens replacement, glaucoma and other eye conditions at each of their locations in northeastern North Carolina. Each office also includes Optometry services, so patients can receive comprehensive eye care from one practice. To learn more about the merger, find a list of providers and services offered by Albemarle Eye Center, or to schedule an appointment, call 252-335-5446, or visit their website at http://www.precisioneyenc.com. To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/albemarle-eye-center-merges-with-two-practices-in-the-east-300464059.html
News Article | June 15, 2017
NEW YORK--(BUSINESS WIRE)--CheckedUp, a specialty point of care company, announced today that advertising icon and digital marketing maverick Jordan Zimmerman and physician, inventor and serial entrepreneur Eugene de Juan, Jr., M.D., have joined the company’s Board of Directors. “We are thrilled to welcome Jordan and Gene to our Board of Directors and look forward to working closely with them as we chart new ground in point of care,” said Richard Awdeh, M.D., CEO and Founder of CheckedUp. “Jordan’s innovations in data-driven brand building and customer conversion, combined with Gene’s experiences as an inventor and entrepreneur, will help us recognize and seize the opportunities ahead to modernize and digitize the clinic, provide actionable health information to the right patient at the right time, and deliver outcomes level data to our practices and partners.” Jordan Zimmerman is Founder, Chairman and architect of Zimmerman Advertising. Established in 1984, the company is now the 14th largest advertising agency in the world with published billings in excess of $3 billion. Zimmerman trademarked his own maverick approach to marketing, “Brandtailing®,” which combines long-term brand building and short-term sales boosting. This methodology is recognized throughout the advertising industry and is the hallmark of Zimmerman’s success with a virtual “who’s who” of marquis consumer brands, including: Nissan, AutoNation, Papa John’s, CBS, Dunkin’ Donuts, Extended Stay America, The Florida Panthers, The Fresh Market, Jamba Juice, Office Depot, Party City, Saks Fifth Avenue, Toys”R”Us and many more. A committed philanthropist, Jordan serves on the Vice Chair of the University of South Florida Board of Trustees, appointed by Governor Rick Scott. He is also a Golden Circle Member of the National MS Society and a generous donor to the Cleveland Clinic Florida, Make-A-Wish Foundation, Jack & Jill Children’s Center, Take Stock in Children, Junior Achievement of South Florida, American Heart Association, American Cancer Society, and Boca Raton Regional Hospital. “CheckedUp operates at the intersections of clinical medicine, patient engagement and practice management,” said Zimmerman. “This challenging environment and the CheckedUp offering are rich with possibilities to utilize data in ways that improve the patient experience, increase practice success, and enhance industry involvement. I am very excited to work with the CheckedUp team to deliver the full promise of this platform.” Eugene de Juan, Jr., M.D., is a renowned retinal surgeon, inventor and entrepreneur. Dr. de Juan currently divides his time between ForSight Labs, where he serves as Vice-Chairman and helps to invent and identify promising ophthalmic devices, and the University of California, San Francisco (UCSF), where he holds the Jean Kelly Stock Distinguished Chair in Ophthalmology. In addition to guiding the translation of innovative ideas generated in the academic center, he continues to see patients, operate and teach at UCSF. Dr. de Juan has participated in the development of more than 100 products in ophthalmology and the founding of nine venture-funded companies including Second Sight, InnoRx, NeoVista, and Retina Labs, as well as ForSight Labs’ first five “VISION” companies: Transcend Medical, Inc., founded in 2005; VISION2 (acquired by QLT, Inc. in 2007); Nexis Vision, Inc. (formerly ForSight VISION3, Inc.), founded in 2007; ForSight VISION4, Inc., founded in 2009; and ForSight VISION5, Inc., founded in 2010. Earlier, Dr. de Juan was a professor of ophthalmology at the University of Southern California (USC) and CEO of the Doheny Eye Institute, focusing on innovative techniques for treating sight-threatening retinal disorders through retinal transplantation, macular translocation, robotic surgery, retinal implants, and other innovative procedures, medicines and instruments, and served at the Wilmer Eye Institute at Johns Hopkins University School of Medicine as Co-Director of Vitreoretinal Service, Director of the Microsurgery Advanced Design Laboratory (MADLAB) and Joseph E. Green Professor of Ophthalmology. From 1983 to 1992, he was a member of the medical staff of the Duke University Eye Center, holding joint teaching appointments with the departments of ophthalmology and cell biology. Dr. de Juan completed his medical degree and internship training at the University of South Alabama College of Medicine. He was a resident at the Wilmer Ophthalmological Institute in Baltimore, MD, and a fellow in vitreoretinal surgery at Duke University. He holds patents on over sixty medical devices and is an author of more than 250 academic publications. “Putting advanced tools for patient education and engagement into the hands of medical practices without creating additional staff burdens is one of the keys to better patient care,” said Dr. de Juan. “CheckedUp has brought all the pieces of this puzzle together and used a range of available technologies in innovative ways to optimize the involvement of patients in their own care. I look forward to helping CheckedUp take the physician-patient relationship to a new level.” CheckedUp is a premier specialty point of care platform that actively engages patients before, during and after visiting the practice leading to higher premium procedure selections, better educated and more confident patients and time savings for the practice. More information is available at www.checkedup.com
News Article | June 6, 2017
Thomas A. Quigley, MD, Ophthalmologist currently on staff at Quigley Eye Specialists, has been named a 2017 Top Doctor in Fort Myers, Florida. Top Doctor Awards is dedicated to selecting and honoring those healthcare practitioners who have demonstrated clinical excellence while delivering the highest standards of patient care. Dr. Thomas A. Quigley is a highly experienced ophthalmologist who has been in practice for about 25 years. Dr. Quigley received his degree in medicine, Magna Cum Laude, from the University of Mississippi where he was a Dean’s Scholar from 1981-1984. Dr. Quigley went on to complete his eye surgery training in Ophthalmology at the LSU Eye Center, Louisiana State University Medical Center in New Orleans. After completing his education and training, Dr. Quigley relocated to Southwest Florida and opened his practice in 1988. Dr. Quigley is certified by the American Board of Ophthalmology and specializes in cataract surgery and SmartLens® procedures. As the leading cataract surgeon in Southwest Florida, Dr. Quigley has performed more than 25,000 cataract surgery procedures without any post-surgical complications or infections, making him one of the most experienced cataract surgeons in the United States. His expertise and dedication make Dr. Quigley a very worthy winner of a 2017 Top Doctor Award. Top Doctor Awards specializes in recognizing and commemorating the achievements of today’s most influential and respected doctors in medicine. Our selection process considers education, research contributions, patient reviews, and other quality measures to identify top doctors.
News Article | June 19, 2017
A new study suggests that most people with acute conjunctivitis, or pink eye, are getting the wrong treatment. About 60 percent of patients are prescribed antibiotic eyedrops, even though antibiotics are rarely necessary to treat this common eye infection. About 20 percent receive an antibiotic-steroid eyedrop that can prolong or worsen the infection. The study is now online in Ophthalmology, the journal of the American Academy of Ophthalmology. This is the first study to assess antibiotic use for pink eye in a large, diverse segment of the United States. The findings are consistent with a nationwide trend of antibiotic misuse for common viral or mild bacterial conditions. It's a trend that increases costs to patients and the health care system and may promote antibiotic resistance. Researchers at the University of Michigan Kellogg Eye Center looked at data from a large managed care network in the United States. They identified the number of patients who filled antibiotic eyedrop prescriptions for acute conjunctivitis. Then they evaluated the characteristics of patients who filled a prescription compared with those who did not. Of approximately 300,000 patients diagnosed with acute conjunctivitis over a 14-year period, 58 percent filled a prescription for antibiotic eye drops. Among them, 20 percent filled a prescription for an antibiotic-steroid combination. Antibiotic-steroid drops are inappropriate for most patients with acute conjunctivitis because it may prolong or exacerbate certain types of viral infection. Even more troubling, the authors found that the odds of filling a prescription depended more on a patient's socioeconomic status than the patient's risk for developing a more serious eye infection. For example, patients who wear contact lenses and those diagnosed with HIV/AIDS. Pink eye affects 6 million people in the United States each year. There are three types: viral, bacterial, and allergic conjunctivitis. Antibiotics are rarely necessary to treat acute conjunctivitis. Most cases are caused by viral infections or allergies and do not respond to antibiotics. Antibiotics are often unnecessary for bacterial conjunctivitis because most cases are mild and would resolve on their own within 7 to 14 days without treatment. "This study opens the lid on overprescribing of antibiotics for a common eye infection," said lead author Nakul S. Shekhawat, M.D., M.P.H. "It shows that current treatment decisions for pink eye are not based on evidence, but are often driven more by the type of health care practitioner making the diagnosis and the patient's socioeconomic status than by medical reasons. The potential negative consequences are difficult to justify as we move toward focusing on value in health care." The authors say there are several reasons why antibiotics are over prescribed. It is a challenge to differentiate bacterial conjunctivitis from the viral and allergic forms. All three types may have overlapping features, such as a red eye, thin discharge, irritation, and sensitivity to light. Health care providers may tend to "err on the side of caution" and prescribe antibiotics "just in case." Patients are often unaware of the harmful effects of antibiotics and may falsely believe that antibiotics are necessary for the infection to resolve. The American Academy of Ophthalmology has issued guidance to the medical community on treatment for pink eye. The Academy tells health care providers to avoid prescribing antibiotics for viral conditions and to delay immediate treatment when the cause of conjunctivitis is unknown.
News Article | May 8, 2017
Acuity Eye Specialists and Dr. Bruce Haight announced that they have entered into a definitive agreement for Acuity Eye Specialists to acquire Grossmont Eye Center, Dr. Bruce Haight’s ophthalmology clinic, in La Mesa, CA. The transaction closed on April 20, 2017. Financial terms were not disclosed. This acquisition is expected to provide Acuity Eye Specialists with an additional clinic and doctors to address the growing needs of patients in the San Diego market, and will increase Acuity Eye Specialists’ footprint in California so they can continue to serve patients throughout the state. “Acquiring Dr. Bruce Haight’s practice is a natural extension for Acuity Eye Specialists as we continue to expand our offerings to help patients access the care they need,” said Tom von Sydow, Chief Operating Officer at Acuity Eye Specialists. "We believe the integration of Dr. Haight’s services into the Acuity Eye Specialists’ platform can further accelerate our leadership and offerings in this growing ophthalmology market." "We are excited to be joining with Acuity Eye Specialists, as our team and patients will greatly benefit from Acuity’s well-established brand and extensive knowledge of the California ophthalmology market," said Dr. Bruce Haight. "Together, we will have the resources to better serve the growing population in San Diego and specifically in La Mesa. Acuity Eye Specialists and I have similar mission-driven cultures with a strong commitment to our patients. I look forward to working together with the Acuity team." This acquisition strengthens Acuity Eye Specialists’ ability to enhance and support its existing patient offerings now and into the future. Acuity Eye Specialists and Dr. Bruce Haight are both committed to providing patients and ophthalmologists access to industry leading research, opportunities to develop clinically so patients receive best-in-class care, and access to effective business support services to streamline the patient visit and better support the doctor. At Acuity Eye Specialists, we are committed to helping ophthalmologists realize their full potential while providing best-in-class patient care to all those in need. We are experts in the business of ophthalmology with years of experience in the industry, a world-class surgeon as our founder, and an unwavering commitment to helping both established practice owners and young professionals further their ophthalmic careers. Headquartered in Pasadena, CA, the Company offers access to ophthalmology services from Fresno to San Diego.